Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2023 Mar 6;25(4):173.
doi: 10.3892/etm.2023.11872. eCollection 2023 Apr.

Synchronous bladder and prostate cancer specimens obtained from radical cystoprostatectomy: A single‑center retrospective analysis

Raffaele Baio  1 , Giovanni Molisso  2 , Christian Caruana  3 , Umberto Di Mauro  2 , Olivier Intilla  2 , Umberto Pane  2 , Costantino D'Angelo  4 , Antonio Campitelli  2 , Francesca Pentimalli  5 , Roberto Sanseverino  2
Affiliations

Synchronous bladder and prostate cancer specimens obtained from radical cystoprostatectomy: A single‑center retrospective analysis

Raffaele Baio et al. Exp Ther Med. .

Abstract

The aim of the present study was to analyze incidence, histopathological features and clinical outcomes of patients undergoing radical cystoprostatectomy (RCP) for bladder cancer, in which incidental prostate cancer (PCa) was found. How these types of cancer impacted the patients' management and whether prostate-sparing cystectomy could be an option for these patients was determined. The current study retrospectively analyzed the data of a cohort of patients from 'Umberto I' Hospital of Nocera Inferiore who underwent RCP for bladder transitional cell carcinoma. Patients with a preoperative diagnosis or clinical suspicion of PCa were excluded. Patients affected by incidental PCa in the RCP specimens were identified, and then their demographic, histopathological and clinical outcome data were collected. Overall, it was revealed that of the 303 patients undergoing RCP for bladder cancer, 69 (22.7%) had incidental PCa, with a median age of 71.6 (age range, 54-89 years). In total, 23 (33.33%) of the 69 patients with incidental PCa were considered to have clinically significant prostate disease. In conclusion, it was relatively common to identify incidental PCa in RCP specimens but no preoperative predictive factors were identified that were able to determine 'non-aggressive' PCa status. Therefore, the present results demonstrate the need for a careful and complete prostate removal during RCP. Nevertheless, since organ-sparing surgeries are widely performed in young population, due to the impossibility of predicting aggressive prostate cancer, these patients require close monitoring through lifelong PSA surveillance, particularly focusing on the possible relapse of PCa after RCP.

Keywords: incidental prostate cancer; prostate sparing surgery; radical cystoprostatectomy.

PubMed Disclaimer

Conflict of interest statement

The authors declare that they have no competing interests.

Figures

Figure 1
Figure 1
Histogram and kernel density estimate of patient age and PSA level. PSA, prostate specific antigen.
Figure 2
Figure 2
Cancer significance distribution between age categories.
See this image and copyright information in PMC

References

    1. Devesa SS, Blot WJ, Stone BJ, Miller BA, Tarone RE, Franmeit JF Jr. Recent cancer trends in the United States. J Natl Cancer Inst. 1995;87:175–182. doi: 10.1093/jnci/87.3.175. - DOI - PubMed
    1. Wingo PA, Tong T, Bolden S. Cancer statistics 1995. CA Cancer J Clin. 1995;45:8–30. doi: 10.3322/canjclin.45.1.8. - DOI - PubMed
    1. Winkler MH, Livni N, Mannion EM, Hrouda D, Christmas T. Characteristics of incidental prostatic adenocarcinoma in contemporary radical cystoprostatectomy specimens. BJU Int. 2007;99:554–558. doi: 10.1111/j.1464-410X.2006.06660.x. - DOI - PubMed
    1. Konski A, Rubin P, Disantagnese PA, Mayer E, Keys H, Cockett A, Frank I, Davis R, Lush C. Simultaneous presentation of adenocarcinoma of prostate and transitional cell carcinoma of bladder. Urology. 1991;37:202–206. doi: 10.1016/0090-4295(91)80285-f. - DOI - PubMed
    1. Witjes JA, Compérat E, Cowan NC, De Santis M, Gakis G, Lebret T, Ribal MJ, Van der Heijden AG, Sherif A. EAU guidelines on muscle-invasive and metastatic bladder cancer: summary of the 2013 guidelines. Eur Urol. 2014;65:778–792. doi: 10.1016/j.eururo.2013.11.046. European Association of Urology. - DOI - PubMed